Lanke Bio Launches EasyGo!™ One-Step ELISA with Proprietary HRP Lyophilized Microsphere Technology and Files IPO Prospectus

The procedure is cumbersome and complex, requiring repeated addition of reagents.ELISAMulti-step incubation methods are not only costly and time-consuming but also prone to errors or deviations in intermediate steps, thereby increasing the risk of experimental failure and raising corporate operational costs. Although one-step methods are convenient, fast, precise, stable, time-saving, and efficient, they have been monopolized by foreign life science giants, resulting in high product prices. Now, Lianke Biology has launched a one-step methodELISAInnovative Technologies and Test KitsEasyGo!™, ChengAmong the very few globally and the first in China to obtain a one-step patent and possess a one-step methodA domestic ELISA kit enterprise propels Chinese-made ELISA technology into the "one-step" era.

EasyGo!™Through LinkoBio's proprietaryHRPLyophilized microsphere technology, in which capture antibodies are pre-coated onto the bottom of an ELISA plate, while detection antibodies (orHRP) formulated into microspheres and pre-loaded into the wells of an ELISA plate, enabling color development with a single-step addition of standards and samples. This eliminates the need for complex procedures such as multi-component reagent preparation and dilution, thereby achieving"Sample in, results out"of the effect, the experimental duration was shortened to90within minutes, while meeting the needs of laboratory personnel for ease of operation, accurate results, and time and labor savings.

July 26Wednesday19：30, VCBeat Selects New Product Tasting No.23Phase, invitedLianke Biologics R&D CenterWang Shuai, ELISA R&D DirectorDr.Introducing One-Step SolutionELISAIntroduction to Innovative Technologies and Kit Products.

Scan the QR code on the poster to add our assistant and reserve your spot for the live stream!

Dr. Shuai Wang

Lianke BiotechR&D Center |ELISA R&D Supervisor

Ph.D., Zhejiang University/Postdoctoral Fellow, Associate Researcher. Dr. Wang has long been dedicated to research in molecular biology and genetics, offering unique insights into immunological diagnostics, and was responsible for developing Lianke Bio’s EasyGo!™One-Step MethodELISA kits. Dr. Wang has published more than 20 research papers, filed five invention patent applications, and undertaken one national-level fund project.

Lianke Biology was established inIn April 2002, after years of development, the company established R&D platforms for ELISA technology and flow cytometry. It is a national high-tech enterprise integrating R&D, production, sales, and services. Lianke Biology has built an innovative and dynamic R&D team comprising professional researchers dedicated to the continuous improvement and innovation of immunology and cell biology products. The company has established GMP-compliant production workshops and manufactures products according to standardized processes. Currently, its proprietary ELISA detection kits have an annual production capacity of 100,000 units, with an output value exceeding RMB 100 million. The company holds more than 10 invention patents, with another 10 invention patents under substantive examination. Lianke Biology is the first domestic enterprise to be listed on the National Equities Exchange and Quotations (NEEQ, also known as the "New Third Board") (Stock Code: 831936), and its quality management system has obtained ISO 9001 international certification.

“Artery Select New Product Launch” is a live-streaming program under “Artery Select” that supports medical enterprises in launching innovative products. The program’s mission is to support the milestone launch of every innovative medical product.

Scan the QR code below to contact the assistant and schedule a live stream.

(If already added, please proactively contact the assistant)